Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

GSK Sets Time Of Tender Offer To Buy Human Genome Sciences To July 20

RELATED NEWS
Trade GSK now with 
6/29/2012 7:26 AM ET

GlaxoSmithKline Plx (GSK: Quote, GSK.L) Friday announced that it has set the time of its tender offer to acquire all of the outstanding shares of Human Genome Sciences (HGSI) at a price of $13.00 per share in cash till 5.00 p.m New York City time on July 20, 2012.

The company stated that the tender offer is due to expire after 16th July 2012, the deadline set by HGS for submission of definitive acquisition proposals in its strategic alternatives review process which began on 19 April after GSK made a private proposal on 11 April.

GSK stated that the time for the expiry of the tender offer till July 20 will provide HGS shareholders the opportunity to evaluate the outcome of the HGS Board's process relative to GSK's offer.

GSK's offer, which is not conditioned on due diligence or financing, represents a premium of 81 percent to HGS's closing share price of US$7.17 on 18 April, the last trading day before HGS publicly disclosed GSK's private offer.

Click here to receive FREE breaking news email alerts for GlaxoSmithKline PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Reserve Bank of New Zealand on Thursday raised its Official Cash Rate by 25 basis points, to 3.00 percent from 2.75 percent. The decision was in line with expectations, and it marks the second straight month with a rate hike following 24 straight meetings in which the rate was not changed. New Zealand's economic expansion has considerable momentum, with GDP estimated to have grown by 3.5 percent in the year to March. Apple Inc. said Wednesday after the markets closed that its second quarter profit rose 7% from last year, as sales surged and margins improved amid strong sales of its iPhones. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. At the same time, the company gave a slightly downbeat revenue forecast for the current quarter. Stocks moved mostly lower during trading on Wednesday, giving back some ground after trending higher over the past several sessions. Selling pressure was relatively subdued, however, limiting the downside for the markets. The major averages all closed in the red, although the tech-heavy Nasdaq underperformed its counterparts by a wide margin.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.